In 1993, the US Food and Drug Adminstration approved the drug Trasylol to be manufactured by Bayer AG. Trasylol, or Aprotinin Injection, is a medication that is given to patients that have had certain types of heart bypass surgery, and is used for clotting blood to aid in the reduction of bleeding or any need for possible blood transfusions. The medication works by decreasing the risk of bleeding by inhibiting certain enzymes.Then in January 2006, two reports were published stating that research was found linking the use of Trasylol to the cause of serious side effects such as kidney failure, stroke, and heart attack. One study was published in The New England Journal of Medicine on January 26, 2006, and suggests that patients that were undergoing coronary artery bypass grafting, or CABG, were at a higher risk for serious side effects associated with the administration of Trasylol. In the report, the occurrence to the serious kidney damage, myocardial infarctions, also known as a heart attacks, and even strokes were described in the CABG patients that were prescribed Trasylol. The report continues on to disclose that more patients are experiencing these events after receiving Trasylol than patients receiving other medications, or even, no medications at all. Yet, another study that was published on January 20, 2006 in the online edition of Transfusion, suggests that patients may be at a greater risk for kidney damage when taking Trasylol.
Trasylol has further been associated with patients suffering from Anaphylactic Reaction due to a rare, but serious, allergic reaction. As this can happen suddenly, and without warning, without immediate medical attention can be life threatening. This risk seems to be increased in patients who have taken Trasylol in the past than with a new dose of the medication.
Later, in October 2007, a Canadian based drug study that was being conducted on cardiac surgery patients was stopped due to Trasylol use appearing to cause increased health risk when compared to other blood clotting medications. Finally on November 5, 2007, Bayer AG announced the worldwide suspension of the sale of Trasylol until such time that drug trials can be more properly evaluated. The FDA and Bayer will continue to seek out the safety benefits of Trasylol during this time of the drug suspension.
Though there is a certain anticipation for any side effects when taking medications, it is the responsibility of the drug manufacturer to make all products reasonably safe, and to inform both the medical community and the public of any known associated risk due to taking any medications. Should a manufacturer choose to not disclose these risks, then the manufacturer can be held legally accountable for any injury that a patient may suffer as the result of inadequate warnings, or even the unreasonably dangerous nature that may be linked to the drug, as a result of product liability.
If there seems to be an experience related to the any dangerous side effects or symptoms that may lead back to the use of Trasylol, then click here to receive a free no obligation consultation.
